Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at HC Wainwright

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock.

Other research analysts have also issued research reports about the company. Barclays lowered Gossamer Bio from an “overweight” rating to an “underweight” rating in a research report on Tuesday, February 24th. Royal Bank Of Canada raised Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a research report on Monday, March 23rd. The Goldman Sachs Group lowered Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Leerink Partners lowered Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Gossamer Bio Price Performance

GOSS opened at $0.21 on Tuesday. The business has a 50 day simple moving average of $0.36 and a two-hundred day simple moving average of $1.74. The firm has a market capitalization of $49.31 million, a price-to-earnings ratio of -0.27 and a beta of 2.15. Gossamer Bio has a one year low of $0.16 and a one year high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Monday, May 18th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $16.96 million during the quarter, compared to analyst estimates of $4.67 million. As a group, sell-side analysts expect that Gossamer Bio will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GOSS. Vanguard Group Inc. grew its stake in shares of Gossamer Bio by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock worth $31,586,000 after buying an additional 598,981 shares during the last quarter. Kalehua Capital Management LLC purchased a new stake in shares of Gossamer Bio in the 1st quarter worth approximately $3,363,000. State Street Corp grew its stake in shares of Gossamer Bio by 139.7% in the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock worth $28,864,000 after buying an additional 5,427,302 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Gossamer Bio by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock worth $15,109,000 after buying an additional 183,183 shares during the last quarter. Finally, Corient Private Wealth LLC grew its stake in shares of Gossamer Bio by 19,123.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after buying an additional 3,825,879 shares during the last quarter. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.